Author's response to reviews

Title: A Phase II Study of LFP Therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-Dose Consecutive (Cisplatin) CDDP) in Advanced Biliary tract Carcinoma

Authors:

Kazuma Kobayashi (bakehasky@eagle.ocn.ne.jp)
Akihito Tsuji (a-tsuji@ma.neweb.ne.jp)
Sojiro Morita (sojiro@mp.mesh.ne.jp)
Tadashi Horimi (horimi@kan.ne.jp)
Tetsuhiko Shirasaka (t-shirasaka@taiho.co.jp)
Takashi Kanematsu (kanematsu@net.nagasaki-u.ac.jp)

Version: 13 Date: 8 April 2006

Author's response to reviews: see over
Author's response to reviews

Title: A Phase II Study of LFP Therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-Dose Consecutive (Cisplatin) CDDP) in Advanced Biliary tract Carcinoma

Authors: Kazuma Kobayashi (bakehasky@eagle.ocn.ne.jp),
Akihito Tsuji (a-tsuji@ma.neweb.ne.jp),
Sojiro Morita (sojiro@mxp.mesh.ne.jp),
Tadashi Horimi (horimi@kcan.ne.jp),
Tetsuhiko Shirasaka (t-shirasaka@taiho.co.jp),
Takashi Kanematsu (kanematsu@net.nagasaki-u.ac.jp)

Reviewer's report
A Phase II Study of LFP Therapy (5-FU (5-fluorourasil) continuous infusion (CVI) and Low-Dose Consecutive (Cisplatin) CDDP) in Advanced Biliary tract Carcinoma

Nicolas Tsavaris Reviewer:

Reviewer's report:
General
In this form the manuscript is sufficient improved. The only point is references where there is a partial confusion. For example:
5th line Introduction “In Japan these malignancies…….surgical resection (6)” and bottom next page “Surgical resection (1,6)”
Reference 1 and 6 are referred about chemotherapy.

It is true that reference 1 and 6 are mainly referred about chemotherapy. But these manuscripts also refer about surgery and prognosis of biliary tract cancer minutely in introduction part. Therefore we adapt these manuscripts on these parts. So we don’t change these parts.

2nd page Introduction, 4th line “single agent chemotherapy has shown poor efficacy (6,8,9), through many efforts has been done (no reference)”
Reference 9 is about surgery
Reference 9 is not about surgery. Truly this manuscript was written by surgeon, but it mainly refers about chemotherapy for biliary tract cancer including pre and post operative chemotherapy.

We changed this part such as the below.

*However, systemic single-agent chemotherapy has so far shown a poor efficacy* (6, 8), *though many efforts has been done* (9).

I think that this is the last correction of the manuscript, and after that the manuscript is going to be acceptable for publication.

Major Compulsory Revisions (that the author must respond to before a decision on publication can be reached)

Minor Essential Revisions (such as missing labels on figures, or the wrong use of a term, which the author can be trusted to correct)

Discretionary Revisions (which the author can choose to ignore)

All the revised parts were underlined in this manuscript. If Tables are difficult to see. Please see the additional file “Tables 1-6 for BMC”.

At last, we appreciate Dr. Nicolas Tsavaris and BMC-cancer for giving a chance to rewrite our manuscripts and painstaking efforts to revise our writings.

Yours sincerely

Kazuma Kobayashi